Business Area
Business Area Labtech
The Labtech business area offers products, solutions and services in, among other things, diagnostics, biomedical research and laboratory analysis. The business area consists of two business units, Biomedical & Research and Diagnostics. The most important customer groups are hospital laboratories, academic research and pharmaceutical companies, mainly in the Nordic region and, to an increasing extent, the rest of Europe.
The business area offers a broad range of products and solutions, including instruments and equipment, consumables and reagents, used to diagnose diseases and conduct research. A large share of sales is linked to installed instruments through public tenders and long‑term agreements, which provides a stable, recurring business based on consumables and service. The business area also provides training, qualified technical service and application support to ensure efficient use of the equipment and strong clinical and research outcomes for customers.
Strengthened position in 2025
As an independent distributor, the companies within Labtech can quickly adapt to changes in suppliers’ strategies and in customer needs. The subsidiaries offer global suppliers a strong commercial organisation with local presence in a growing number of European countries, enabling the launch of new technologies on a broad scale while remaining close to customers. In 2025, the Labtech subsidiaries continued to strengthen their position in prioritised growth segments such as advanced molecular diagnostics, gene sequencing (NGS), blood gas, immunology and digital pathology. These areas are characterised by higher growth and healthy margins, which contributed to a further improvement in the business area’s profitability during the year. Currency‑adjusted organic growth amounted to 5 percent and acquired growth to 1 percent. EBITA increased by 11 percent and the EBITA margin was 12.5 percent (11.7).
| SEKm | 2025 | 2024 | 2023 |
| Net sales | 3,953 | 3,797 | 3,654 |
| EBITA | 495 | 445 | 473 |
| EBITA margin, % | 12.5 | 11.7 | 12.9 |
| Adjusted EBITA | 495 | 445 | 445 |
| Adjusted EBITA margin, % | 12.5 | 11.7 | 11.7 |
| Number of employees | 817 | 790 | 805 |
| Organic growth | |||
| Total growth, % | 4.1 | 4.0 | -5.8 |
| (-) Currency effect, % | -2.7 | -0.5 | 4.7 |
| (-) Acquired growth, % | 1.4 | 1.6 | 0.7 |
| Organic growth, % | 5.4 | 2.9 | -11.2 |
Market development 2025
Demand for consumables related to diagnostics and laboratory operations remained stable and continued to grow in 2025. Tenders won in recent years continued to contribute positively through higher volumes of reagents and other consumables. At the same time, the willingness to invest in larger instrument deals remained restrained in certain parts of academic research, where budget pressures and longer decision‑making processes persisted.
Several global suppliers continued to adjust their go‑to‑market strategies, which created opportunities for the Labtech companies to take over product portfolios, win tenders from competitors and broaden their offerings in selected niches. Work to strengthen the presence in the prioritised segments in microbiology, molecular diagnostics, genetic testing and advanced research instruments progressed according to plan. This strategic focus means that Labtech is gradually increasing the share of advanced products with higher value and profitability, thereby strengthening both the business area’s growth profile and margins.
LABTECH’S STRENGTHS
- Committed employees with a high level of education and many years of experience in their specialist fields
- High quality in products, service, training programmes and advisory services
- Long‑term partnerships with leading suppliers and exclusive distribution rights
- Well‑developed technical service organisation with a strong local presence close to customers
- Attractive business model with low capital tied up
Acquisitions
In December, Pharmacold A/S in Denmark was acquired, a company specialised in refrigeration technology and service for the pharmaceutical and healthcare sectors. The acquisition strengthens Labtech’s offering in temperature‑sensitive handling of pharmaceuticals and samples, an area with increasing requirements for quality, safety and documentation.
Product segments within Labtech
BIOMEDICAL & RESEARCH
- Advanced instruments
- Plastic consumables
- General lab equipment
- Cell biology
- Reagents
DIAGNOSTICS
- Microbiology
- Molecular genetics
- Clinical chemistry
- Immunology
- Haematology
- Cytology and pathology
- Point‑of‑care
Biolin Scientific - experts in surface and interface analysis
With 30 years of experience, a strong global presence and a focus on research‑driven innovation in advanced surface and interface analysis, Biolin Scientific is a key driver of scientific progress. The company’s solutions help both academic and industrial researchers achieve excellent results and contribute to academic innovation as well as high‑impact research and development.
Subsidiaries within Labtech
